TransMedics Group, Inc. (TMDX) stock
TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3029% below fair value
$93.91+1.70 (+1.84%)
Close on Nov 17, 2026Market cap $3.26BP/E 24.4Yield 0.00%
TransMedics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
TransMedics's price to sales ratio was 4.8× on Nov 11, 2026, against 8.8× a year earlier. Over the last 5 years it ranged from 3.4× to 28.9×, with a median of 12.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.8× | −2.6 |
| 2025 | Dec 31, 2025 | 7.3× | +2.1 |
| 2024 | Dec 31, 2024 | 5.2× | −8.2 |
| 2023 | Dec 29, 2023 | 13.4× | −14.0 |
| 2022 | Dec 30, 2022 | 27.5× | +8.6 |
| 2021 | Dec 31, 2021 | 18.9× | −3.6 |
| 2020 | Dec 31, 2020 | 22.5× | +14.1 |
| 2019 | Dec 31, 2019 | 8.4× | – |
See a number that looks wrong?